Basel, June 21, 2022 Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding the validity of US Patent No.
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 - Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding the
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit issued a new, negative decision regarding. | June 21, 2022
Basel, January 4, 2022 Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity.